Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Eisai Co., Ltd.
  6. News
  7. Summary
    4523   JP3160400002

EISAI CO., LTD.

(4523)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eisai : Starts Rolling Submission To Seek US Approval For Alzheimer's Disease Therapy

09/28/2021 | 03:20am EST


© MT Newswires 2021
All news about EISAI CO., LTD.
05:45aEisai Co - European Commission Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizum..
AQ
05:45aEisai - European Commission Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab)..
AQ
11/29Eisai and FCNT Enter Into Business Alliance Aiming to Support People Living with Dement..
AQ
11/29EISAI : AND FCNT ENTER INTO BUSINESS ALLIANCE AIMING TO SUPPORT PEOPLE LIVING WITH DEMENTI..
PU
11/29EISAI : To present latest data on perampanel and e2730 at the 75th american epilepsy socie..
PU
11/29Merck, Eisai Get Europe OK for Lenvima/Keytruda Combination in Two Cancers
DJ
11/28European Commission Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) for Pat..
AQ
11/28European Commission Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as Firs..
AQ
11/28EISAI : European Commission Approves LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) ..
PU
11/28EISAI : European Commission Approves LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) ..
PU
More news
Analyst Recommendations on EISAI CO., LTD.
More recommendations
Financials
Sales 2022 708 B 6 248 M 6 248 M
Net income 2022 57 052 M 504 M 504 M
Net cash 2022 147 B 1 301 M 1 301 M
P/E ratio 2022 34,5x
Yield 2022 2,35%
Capitalization 1 970 B 17 377 M 17 397 M
EV / Sales 2022 2,58x
EV / Sales 2023 2,49x
Nbr of Employees 11 237
Free-Float 87,9%
Chart EISAI CO., LTD.
Duration : Period :
Eisai Co., Ltd. Technical Analysis Chart | 4523 | JP3160400002 | MarketScreener
Technical analysis trends EISAI CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Last Close Price 6 873,00 JPY
Average target price 10 150,77 JPY
Spread / Average Target 47,7%
EPS Revisions
Managers and Directors
Haruo Naito Chief Executive Officer & Representative Director
Ryohei Yanagi Chief Financial Officer
Yasuhiko Katoh Chairman
Edward Stewart Geary Chief Medical Officer & Managing Executive Officer
Lynn D. Kramer Chief Medical & Chief Clinical Officer-Neurology
Sector and Competitors
1st jan.Capi. (M$)
EISAI CO., LTD.-6.77%17 767
JOHNSON & JOHNSON1.16%420 557
ROCHE HOLDING AG15.70%334 662
PFIZER, INC.42.35%294 114
NOVO NORDISK A/S67.75%247 392
ELI LILLY AND COMPANY50.93%231 027